Advancing opportunities in treating rare diseases, giving patients an improved quality of life and better outcomes.
Through innovative research and development, quality manufacturing and years of experience, as well as listening and learning from patients, we aim to improve the lives of those suffering from rare diseases across the UK.
Quality and safety are our top priorities. Our medicines are manufactured in state-of-the-art production facilities. We track each of our drugs from creation to the finished product to ensure its pharmaceutical and therapeutic quality. These high quality standards ensure we deliver the treatments patients deserve.
The well-being of people is our focus. Our class leading products and dedicated employees, demonstrate our commitment to providing medical solutions that can benefit all those involved in the healthcare system.
We have a commitment to deliver world class treatments. A commitment to society, our employees and patients. Rigorous research, rigorous manufacturing and rigorous standards deliver innovative solutions and are supported by our CSR Annual Report, Social Projects, Patient Support and Transparency.
Our employees are our greatest asset and are committed to creating the most effective solutions for rare diseases. With a transparent, flexible and participative work place they are given the autonomy to achieve their ambitions. And by empowering them, we are empowering patients suffering from rare diseases.
We value our employees by offering them a professional environment, equal opportunities and a genuine work-life balance. We ensure our products, wherever possible, are accessible to all and offer flexible solutions to HCPs and patients.
Since 2023, ITALFARMACO has been in the UK with its ITF Pharma UK subsidiary offering future-oriented medical care and tailor-made services. The UK company will be initially focused on developing new rare disease treatments, specifically targeting Duchenne Muscular Dystrophy.
As there is currently no cure for DMD, it represents an area of high unmet medical need. DMD is a fatal genetic condition that causes the progressive weakening and degeneration of muscles. It affects an estimated 2,500 people in the UK and Ireland and there is currently no cure. Thankfully, the UK offers a phenomenal array of partnerships in the management and research of DMD, alongside a positive patient environment that’s supported by patient groups, charities and specialist healthcare provider networks fighting on every front to transform the lives of people impacted by DMD.
ITF Pharma UK is committed and motivated to making a real difference in DMD and aims to harness the unique expertise of our dedicated UK team. Together with the experience and support of the ITALFARMACO group we are well placed to provide added value to the DMD community. Being in the UK allows us to be in the same space as other world leading companies, collectively striving to solve the challenges of DMD. We are passionate and determined in our quest to drive life-changing innovation, ground-breaking science, and provide progressive treatments that can support patients with DMD long term.
ITALFARMACO operates 7 state-of-the-art production facilities worldwide, which meet the highest international quality standards. Existing facilities were modernised and new production lines were expanded. ITALFARMACO constantly invests in technology to have modern, flexible facilities and a high production capacity, so patients across the world can rely on us to deliver the treatments they need.